💡 <0>Get more than just numbers.</0> Subscribe to access AI-powered analysis of company reports — key trends and metrics in a simple, easy-to-understand format.

My notes

My positions

Up-to-date information about stocks, bonds, funds and cryptocurrencies. Quotes, information about dividends and payment history, reporting of companies for 10 years, comparison of companies with each other.

Real-time data for {{ticker}} ({{description}}) on {{exchange}}. Dividend history, payout dates, yield, and fundamental analysis on Snowball Analytics.

{{description}} ({{ticker}}) Stock Price, Dividends & History | Snowball Analytics

This place looks empty

Benchmarks

 Outstanding nominal value as of the current date

Average price of a bond, in % of face value

The current yield indicates the ratio of the accrued coupon to the current market price of the bond. It can be used in cases where attachments are considered for a short period of time. In this situation, the change in the market price can sometimes be neglected.

Bond duration is a way of measuring how much bond prices are likely to change if and when interest rates move.

Effective yield to maturity. It considers both coupon income and profit/loss due to the difference between the purchase price and the repayment price. Effective yield shows the investor the return on invested funds with reinvested coupons and depreciation.

Listing level — stock exchange assessment of securities reliability.

The ratio of the annual coupon to the "dirty" price of the bond, including the accrued interest. This type of yield can be used in the case of short-term investments, when the investment horizon is within one coupon period.

Average purchase price of a bond, in % of face value

Bond issue credit ratings from ACRA / Expert RA rating agencies. The higher the rating, the lower the estimated credit risk. A rating is not a guarantee and does not replace your own analysis.

Issuer credit rating from rating agency <0>{{agency}}</0> as of <1></1>

Issuer credit rating from rating agency <0>{{agency}}</0> - {{value}}

Bond issue credit rating from rating agency <0>{{agency}}</0> dated <1></1>

Bond issue credit rating from rating agency <0>{{agency}}</0> — {{value}}

Up to 2 years - short-term, up to 5 years - mid-term, more than 5 years - long-term

Bond type - goverment, municipal or corporate

Coupon yield % per annum of nominal value (coupon amount per year/nominal value)

 Simple yield to maturity. It considers both coupon income and profit/loss due to the difference between the purchase price and the repayment price. Simple yield shows the investor the return on invested funds without reinvested coupons.

Stay updated with the latest market trends and discover new growth opportunities with our blog.

New and interesting articles

The fund expense ratio is the annual fee expressed as a percentage of a mutual fund or ETF's average assets, covering management, administrative, and other operational costs. It directly reduces investors' returns.

10 years

12 trailing months

1 day

1 month

1 year

3 months

5 years

6 months

1 week

all time

Choose a period

year to date

Full list of latest news and articles is available with our "Starter", "Investor" plans

Your {{name}} file was successfully downloaded and is ready to use.

✅ Download complete

Your {{name}} is on its way! If there's an issue, try again or check your browser settings.

⏳ Downloading in progress

Portfolio report

Get the full picture of your investments — subscribe to Investor or Expert for deeper insights.

Expert

Investor

What's included:

🚀 Upgrade your plan to unlock full report

Subscription change

We will be happy to receive your feedback

Why did you decide to cancel your subscription?

Simple pricing, for

every investor

Unlock advanced analytics with Snowball Analytics comprehensive pricing plans. Tailored for individuals, startups, and enterprises, our packages offer valuable insights to propel your investment strategies forward

Explore Pricing Plans and Pricing Dividend Tracker at Snowball Analytics

Welcome to {{name}}

Take full control of your investments

"<0></0>" plan limits

Choose a plan and start making the most out of your investments today

Maximize your portfolio's potential by using all our features designed to help you stay on top of your financial goals

Couldn't apply this code

Yay, you've got your discount!

I have a discount code!

Would you like to have the same portfolio?

Plans & Pricing - Snowball Analytics

Start your journey to financial independence

Disable 2FA

Get your authenticator app

Recovery codes

Enable two-factor authentication

Password login required

These are the backup codes for the Snowball Analytics account. Store them securely and keep them secret. Each code can only be used once.

Recovery codes can be used for authorization if you do not have access to your device.

Effective protection against hacking: in order to log in, you should enter a one-time code. If you're using external login (via Google, Apple) please enable 2FA there.

Two-Factor Authentication (2FA)

Get codes from an authentication app on your mobile device (ex. Google Authenticator, Authy, ...).

Login via Authentication app

Something went wrong

You have unsubscribed successfully

Unsubscribe from all emails

An email will be send to you with instructions on how to change your password, please check your email.

Delete my account

Account removal

You can cancel anytime but it will be active until the end of the paid period.

Our service functions on the basis of subscriptions. You can choose an annual or monthly subscription type. The fee will be charged once a year or a month, respectively.

🎉 Success!

Oops, the payment has failed

Subscription renewal

Emails about newly declared dividends. Available on our premium plans only.

Emails about dividend payment dates. Available on our premium plans only.

Emails about ex-dividend dates. Available on our premium plans only.

The payment history to your account is displayed here

All payments of your users and your remuneration are displayed here

Post the link to the Snowball Analytics on your blog or publish it on social networks

for the first two years since the user's registration, after that your remuneration will be

for the first two years since the user's registration

Terms of our partner program

All users who have been registered using your referral link are displayed here

Post your personal link to Snowball Analytics on your blog or social networks

Registered users are eligible for a 10% discount for the next purchase

You will receive 40% from every payment in first two years

Please write us an email to receive more information:

Earn with the Snowball Analytics

You can manage your subscription directly in App Store or you can cancel it there and subscibe using our native subscription plans.

Your subsciption works via Apple App Store.

Your subscription is cancelled. Subscribe to take advantage of all the benefits {{app}}

Your subscription is expired. Subscribe to keep receiving the benefits {{app}}

{{portfoliosCount}} portfolio, {{assetsCount}} assets

{{portfoliosCount}} number of portfolios, {{assetsCount}} amount of assets

{{portfoliosCount}} of your portfolio, {{assetsCount}} assets count

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Rigel Pharmaceuticals Inc

Frequently asked questions

What sector does Rigel Pharmaceuticals Inc (RIGL) operate in?

What is Rigel Pharmaceuticals Inc (RIGL) current stock price?

What is Rigel Pharmaceuticals Inc (RIGL) current market capitalization?

What is Rigel Pharmaceuticals Inc (RIGL) Earnings Per Share (EPS)?

What is Rigel Pharmaceuticals Inc (RIGL) Price-to-Earnings (P/E) ratio?

What is Rigel Pharmaceuticals Inc (RIGL) EBITDA?

Does Rigel Pharmaceuticals Inc (RIGL) pay dividends?

How did Rigel Pharmaceuticals Inc (RIGL) perform in its most recent earnings report?

What is Rigel Pharmaceuticals Inc (RIGL) beta (volatility) score?